Last year, Sepracor, the maker of sleeping pill Lunesta, announced it would reduce its sales and marketing expenses by $90-100 million in 2008, "including an anticipated reduction of approximately 300 ...

Sepracor will eliminate 300 sales force positions as part of a cost cutting plan to reduce expenses by $90 million-$100 million for 2008. “We have examined our sales organization in depth,” Adrian ...

Sepracor will launch a $60 million dollar marketing and advertising campaign for its new sleeping pill Lunesta in the coming week. Ads for the drug will tout Lunesta’s advantages, Sepracor chief ...

Holders of Sepracor stock considering Dainippon Sumitomo Pharma's offer of $23 a share to take over the company might want to ask themselves, Might this company be willing to pay more than a 27.6 ...

During the last year, Sepracor (SEPR) has had a substantial correction in price, dropping over fifty percent. This significant decline has taken the market cap of the company to only $3.11B. Even with ...

Marlborough-based drug maker Sepracor Inc. has hired four new executives from Novartis and GlaxoSmithKline. Sepracor's most recognizable and most successful product is the sleep drug Lunesta. The new ...

Overall planned operating expense reduction of approximately $210.0 million, of which approximately $20.0 million of cost savings was realized in the fourth quarter of 2008 and approximately $190.0 ...

Marlborough pharmaceutical company Sepracor Inc. says a phase III study of its nasal aerosol hay fever treatment had positive results. The company said the treatment, OMNARIS HFA, reduced nasal ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. and Dainippon Sumitomo Pharma Co., Ltd. (DSP) today announce the resignation of Adrian Adams as President and Chief Executive Officer and Director of ...

MARLBOROUGH, Mass. (CBS.MW) - Sepracor Inc. rose from obscurity to become a Wall Street darling in the late '90s as investors bet that the company could capture a big piece of the lucrative market for ...

Sepracor Inc. and Dainippon Sumitomo Pharma Co., Ltd. (DSP) today announce the resignation of Adrian Adams as President and Chief Executive Officer and Director of Sepracor and as Executive Officer of ...